These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29396668)

  • 1. Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy.
    Al-Subhi N; Ali R; Abdel-Fatah T; Moseley PM; Chan SYT; Green AR; Ellis IO; Rakha EA; Madhusudan S
    Breast Cancer Res Treat; 2018 Jun; 169(2):277-286. PubMed ID: 29396668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abrogation of ATR function preferentially augments cisplatin-induced cytotoxicity in PTEN-deficient breast cancer cells.
    Zhao JL; Yang J; Li K; Chen Y; Tang M; Zhu HL; Nie CL; Yuan Z; Zhao XY
    Chem Biol Interact; 2023 Nov; 385():110740. PubMed ID: 37802411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.
    Sultana R; Abdel-Fatah T; Perry C; Moseley P; Albarakti N; Mohan V; Seedhouse C; Chan S; Madhusudan S
    PLoS One; 2013; 8(2):e57098. PubMed ID: 23451157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer.
    Abdel-Fatah TM; Middleton FK; Arora A; Agarwal D; Chen T; Moseley PM; Perry C; Doherty R; Chan S; Green AR; Rakha E; Ball G; Ellis IO; Curtin NJ; Madhusudan S
    Mol Oncol; 2015 Mar; 9(3):569-85. PubMed ID: 25468710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers.
    Savva C; De Souza K; Ali R; Rakha EA; Green AR; Madhusudan S
    Breast Cancer Res Treat; 2019 May; 175(1):105-115. PubMed ID: 30746633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of DNA Replication Stress by CHK1 Leads to Chemoresistance Despite a DNA Repair Defect in Homologous Recombination in Breast Cancer.
    Meyer F; Becker S; Classen S; Parplys AC; Mansour WY; Riepen B; Timm S; Ruebe C; Jasin M; Wikman H; Petersen C; Rothkamm K; Borgmann K
    Cells; 2020 Jan; 9(1):. PubMed ID: 31963582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATM inhibition induces synthetic lethality and enhances sensitivity of PTEN-deficient breast cancer cells to cisplatin.
    Li K; Yan H; Guo W; Tang M; Zhao X; Tong A; Peng Y; Li Q; Yuan Z
    Exp Cell Res; 2018 May; 366(1):24-33. PubMed ID: 29522753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer.
    Tu X; Kahila MM; Zhou Q; Yu J; Kalari KR; Wang L; Harmsen WS; Yuan J; Boughey JC; Goetz MP; Sarkaria JN; Lou Z; Mutter RW
    Mol Cancer Ther; 2018 Nov; 17(11):2462-2472. PubMed ID: 30166399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Withaferin A inhibits expression of ataxia telangiectasia and Rad3-related kinase and enhances sensitivity of human breast cancer cells to cisplatin.
    Hahm ER; Lee J; Abella T; Singh SV
    Mol Carcinog; 2019 Nov; 58(11):2139-2148. PubMed ID: 31441116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance.
    Zheng H; Shao F; Martin S; Xu X; Deng CX
    Sci Rep; 2017 Mar; 7():43517. PubMed ID: 28262781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
    Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
    Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy.
    Albarakati N; Abdel-Fatah TM; Doherty R; Russell R; Agarwal D; Moseley P; Perry C; Arora A; Alsubhi N; Seedhouse C; Rakha EA; Green A; Ball G; Chan S; Caldas C; Ellis IO; Madhusudan S
    Mol Oncol; 2015 Jan; 9(1):204-17. PubMed ID: 25205036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic enhancement of apoptosis by coralyne and paclitaxel in combination on MDA-MB-231 a triple-negative breast cancer cell line.
    Kumari S; Mohan MG; Shailender G; Badana AK; Malla RR
    J Cell Biochem; 2019 Oct; 120(10):18104-18116. PubMed ID: 31172606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the ATR-DNAPKcs-RB axis drives G1/S-phase transition and sensitizes triple-negative breast cancer (TNBC) to DNA holliday junctions.
    Hu YM; Liu XC; Hu L; Dong ZW; Yao HY; Wang YJ; Zhao WJ; Xiang YK; Liu Y; Wang HB; Yin QK
    Biochem Pharmacol; 2024 Jul; 225():116310. PubMed ID: 38788960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ATR inhibition by Elimusertib enhances the radiosensitivity of MDA-MB-231 triple negative breast cancer in vitro.
    Guney Eskiler G; Halis H; Hamarat KF; Derlioglu RR; Ugurlu BT; Haciefendi A
    Int J Radiat Biol; 2024; 100(5):715-723. PubMed ID: 38421209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer.
    Alsubhi N; Middleton F; Abdel-Fatah TM; Stephens P; Doherty R; Arora A; Moseley PM; Chan SY; Aleskandarany MA; Green AR; Rakha EA; Ellis IO; Martin SG; Curtin NJ; Madhusudan S
    Mol Oncol; 2016 Feb; 10(2):213-23. PubMed ID: 26459098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of action studies of lomaiviticin A and the monomeric lomaiviticin aglycon. Selective and potent activity toward DNA double-strand break repair-deficient cell lines.
    Colis LC; Hegan DC; Kaneko M; Glazer PM; Herzon SB
    J Am Chem Soc; 2015 May; 137(17):5741-7. PubMed ID: 25849366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.
    Kim HJ; Min A; Im SA; Jang H; Lee KH; Lau A; Lee M; Kim S; Yang Y; Kim J; Kim TY; Oh DY; Brown J; O'Connor MJ; Bang YJ
    Int J Cancer; 2017 Jan; 140(1):109-119. PubMed ID: 27501113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand.
    Mei L; Zhang J; He K; Zhang J
    J Hematol Oncol; 2019 Apr; 12(1):43. PubMed ID: 31018854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic lethality between ATR and POLA1 reveals a potential new target for individualized cancer therapy.
    Schneider HE; Schmitt LM; Job A; Lankat-Buttgereit B; Gress T; Buchholz M; Gallmeier E
    Neoplasia; 2024 Nov; 57():101038. PubMed ID: 39128273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.